Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat TumorsGlobeNewsWire • 11/10/22
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in NovemberGlobeNewsWire • 10/11/22
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced TumorsGlobeNewsWire • 09/10/22
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate UpdatesGlobeNewsWire • 08/30/22
Adagene Announces Authorization of Share Repurchase Program up to US$10 MillionGlobeNewsWire • 06/29/22
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose LevelsGlobeNewsWire • 05/26/22
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 04/08/22
Adagene Reports Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/31/22
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid TumorsBenzinga • 03/16/22
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody PembrolizumabGlobeNewsWire • 03/16/22
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/08/22
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody CandidatesGlobeNewsWire • 03/02/22
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/08/22
Adagene Announces Board and Management Appointments to Support Pipeline GrowthGlobeNewsWire • 02/02/22
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116GlobeNewsWire • 01/27/22
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.GlobeNewsWire • 01/19/22
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in SingaporeGlobeNewsWire • 01/13/22
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate CandidatesGlobeNewsWire • 12/22/21
Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™GlobeNewsWire • 12/13/21